Abstract:
stiffness in Alzheimer’s disease
Fulltext
Metrics
Get Permission
Cite this article
Authors Bektaş O, Günaydın Z, Karagöz A, Kaya A
Received 31 December 2014
Accepted for publication 31 December 2014
Published 13 February 2015 Volume 2015:10 Pages 469—471
DOI https://doi.org/10.2147/CIA.S80096
Checked for plagiarism Yes
Editor who approved publication: Dr Richard Walker
Download Article [PDF]
Osman Bektaş,1 Zeki Yüksel Günaydin,1 Ahmet Karagöz,2 Ahmet Kaya1
1Ordu University, Department of Cardiology, Ordu, 2Giresun University, Department of Cardiology, Giresun, Turkey
We have read the original research entitled "Altered diastolic function and aortic stiffness in Alzheimer’s disease" by Çalık et al1 which was published in the July 2014 issue of Clinical Interventions in Aging, with great interest. We would like to touch on some points about this article.
View original paper by Çalık and colleagues
Firstly, when clinical and demographic characteristics were evaluated, it was stated that the study and control groups included eleven (37%) and 14 (58%) hypertensive (P=0.14) and four (13%) and four (16%) diabetic (P=0.77) patients, respectively. It is obvious that there was no significant difference between the two groups in terms of these diseases, which are likely to affect aortic stiffness. On the other hand, lack of an explanation about use of antihypertensive and antidiabetic medication is conspicuous. We suggest that use of antihypertensive and antidiabetic therapy should also be similar between the study and control groups since antihypertensive and antidiabetic drugs have already been shown to affect arterial stiffness to various degrees. Angiotensin-converting enzyme inhibitors have been shown to improve arterial compliance,2 and angiotensin receptor blockers are also likely to have effects similar to those of angiotensin-converting enzyme inhibitors.3 When compared with vasodilating drugs from other groups, beta-blockers have a weaker effect on arterial stiffness and central pulsatile hemodynamics.4 Calcium channel blockers also lower pulse wave velocity and reduce wave reflections,5 although to a lesser extent than renin-angiotensin inhibitors. Further, diuretics seem to have no beneficial effect on pulsatile hemodynamics.6 On the other hand, in the diabetic population, glitazones and peroxisome proliferator-activated receptor gamma agonists have been shown to decrease arterial stiffness in addition to having favorable effects on insulin resistance and glycemic control. Although the study and control groups included similar proportions of hypertensive and diabetic patients, these studies show that aortic stiffness is affected by antihypertensive and antidiabetic treatment. Therefore, in our opinion, it is essential to report all medications used by patients.7,8
Secondly, the status of the patients with regard to lipid profile and statin use is also not mentioned in the study. The lipid profile of patients in the study and control groups and status of statin use are important and should be stated in the article, because statins (HMG-CoA reductase inhibitors) provide additional protective/beneficial (pleiotropic) effects on the cardiovascular system in addition to their basic action in reducing low-density lipoprotein cholesterol. Although conflicting reports exist, statins are thought to improve arterial stiffness directly.